FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765735006> ?p ?o ?g. }

• W2765735006 abstract "The Dependence Scale (DS) captures a combination of the cognitive, functional, and psychiatric changes that occur in Alzheimer's disease (AD) and is strongly correlated with cost of patient care. As reported previously, combination therapy with donepezil and 35 mg intepirdine (RVT101), an oral 5HT6 antagonist in development for the treatment of mild-moderate AD, was projected based on a conversion algorithm to reduce progression in Dependence Level (DL) compared to donepezil monotherapy using data from a placebo-controlled study. Here we examine potential Medicare cost differences associated with this reduced DL progression. The Alzheimer's Disease Cooperative Study – Activities of Daily Living Scale (ADCS-ADL) was measured in a 48-week study of intepirdine vs. placebo, on top of stable donepezil, in subjects with mild to moderate AD (n=684). The ADCS-ADL was converted to DL using a published algorithm. Total costs were estimated from the Predictors 2 study using Medicare costs and assigned to this study. Informal caregiving costs were not included. Cost changes from baseline were compared between treatment groups. Estimated Medicare costs were higher at more severe DLs, ranging from $2,684 for DL=0/1 to $11,218 for DL=4/5. Annual costs associated with the donepezil monotherapy group were projected to increase by an average of $356 over all visits, while annual costs associated with the 35 mg intepirdine plus donepezil combination therapy group were projected to decrease by $42. The magnitude of annual cost benefit associated with intepirdine treatment was projected to range from $289 to $372 based on baseline DL. In this analytical framework, combination therapy with 35 mg intepirdine and donepezil was associated with projected annual cost benefits for Medicare between $289 and $372 compared to donepezil monotherapy. Intepirdine is currently being evaluated in a global Phase 3 study in mild-moderate AD with data expected in 2017." @default.
• W2765735006 created "2017-11-10" @default.
• W2765735006 creator A5032025339 @default.
• W2765735006 creator A5044970030 @default.
• W2765735006 creator A5071321317 @default.
• W2765735006 creator A5083471801 @default.
• W2765735006 creator A5087302628 @default.
• W2765735006 date "2017-07-01" @default.
• W2765735006 modified "2023-09-27" @default.
• W2765735006 title "AN ANALYTICAL FRAMEWORK TO PROJECT THE POTENTIAL MEDICARE COST BENEFIT OF INTEPIRDINE (RVT101) IN MILD-MODERATE ALZHEIMER'S DISEASE" @default.
• W2765735006 doi "https://doi.org/10.1016/j.jalz.2017.07.715" @default.
• W2765735006 hasPublicationYear "2017" @default.
• W2765735006 type Work @default.
• W2765735006 sameAs 2765735006 @default.
• W2765735006 citedByCount "1" @default.
• W2765735006 countsByYear W27657350062020 @default.
• W2765735006 crossrefType "journal-article" @default.
• W2765735006 hasAuthorship W2765735006A5032025339 @default.
• W2765735006 hasAuthorship W2765735006A5044970030 @default.
• W2765735006 hasAuthorship W2765735006A5071321317 @default.
• W2765735006 hasAuthorship W2765735006A5083471801 @default.
• W2765735006 hasAuthorship W2765735006A5087302628 @default.
• W2765735006 hasBestOaLocation W27657350061 @default.
• W2765735006 hasConcept C126322002 @default.
• W2765735006 hasConcept C142724271 @default.
• W2765735006 hasConcept C1862650 @default.
• W2765735006 hasConcept C204787440 @default.
• W2765735006 hasConcept C27081682 @default.
• W2765735006 hasConcept C2779134260 @default.
• W2765735006 hasConcept C2779483572 @default.
• W2765735006 hasConcept C2780904820 @default.
• W2765735006 hasConcept C71924100 @default.
• W2765735006 hasConcept C74909509 @default.
• W2765735006 hasConcept C79544238 @default.
• W2765735006 hasConceptScore W2765735006C126322002 @default.
• W2765735006 hasConceptScore W2765735006C142724271 @default.
• W2765735006 hasConceptScore W2765735006C1862650 @default.
• W2765735006 hasConceptScore W2765735006C204787440 @default.
• W2765735006 hasConceptScore W2765735006C27081682 @default.
• W2765735006 hasConceptScore W2765735006C2779134260 @default.
• W2765735006 hasConceptScore W2765735006C2779483572 @default.
• W2765735006 hasConceptScore W2765735006C2780904820 @default.
• W2765735006 hasConceptScore W2765735006C71924100 @default.
• W2765735006 hasConceptScore W2765735006C74909509 @default.
• W2765735006 hasConceptScore W2765735006C79544238 @default.
• W2765735006 hasIssue "7S_Part_32" @default.
• W2765735006 hasLocation W27657350061 @default.
• W2765735006 hasOpenAccess W2765735006 @default.
• W2765735006 hasPrimaryLocation W27657350061 @default.
• W2765735006 hasRelatedWork W1948364294 @default.
• W2765735006 hasRelatedWork W1989703975 @default.
• W2765735006 hasRelatedWork W1997886955 @default.
• W2765735006 hasRelatedWork W2011091925 @default.
• W2765735006 hasRelatedWork W2058879779 @default.
• W2765735006 hasRelatedWork W2136332296 @default.
• W2765735006 hasRelatedWork W2489612427 @default.
• W2765735006 hasRelatedWork W2584314249 @default.
• W2765735006 hasRelatedWork W2765663184 @default.
• W2765735006 hasRelatedWork W2030079540 @default.
• W2765735006 hasVolume "13" @default.
• W2765735006 isParatext "false" @default.
• W2765735006 isRetracted "false" @default.
• W2765735006 magId "2765735006" @default.
• W2765735006 workType "article" @default.